crohn's glp 1 A surprising role for enteroendocrine cells and GLP-1 in regulating intestinal inflammation Crohn's disease is a type

Multiple randomised, placebo-controlled trials have tested GLP-1 drugs as add-on therapy to insulin in people with T1D, and the picture that emerges is consistent, if modest: meaningful weight loss, real reductions in daily insulin needs, and improvements in CGM time in range

Keto as a maintenance strategy after stopping semaglutide Weight regain after stopping GLP-1 medications is a real and well-documented phenomenon

Some patients focus primarily on weight management, while others are interested in recovery, sleep improvement, healthy aging, or overall wellness optimization

Effect of levocarnitine administration in patients with chronic liver disease

Stem cell therapy as a potential treatment option for psoriasis